Loading clinical trials...
Loading clinical trials...
A Phase 1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells After Partially Mismatched, Related, T Cell-Depleted HSCT (Hematopoietic Stem Cell Transplant)
Conditions
Interventions
BPX-501 dose 1
Rimiducid
+4 more
Locations
8
United States
Emory University Winship Cancer Institute
Atlanta, Georgia, United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
University Hospitals of Cleveland
Cleveland, Ohio, United States
Oregon Health & Science University
Portland, Oregon, United States
Baylor Sammons Cancer Center
Dallas, Texas, United States
Start Date
March 1, 2013
Primary Completion Date
October 9, 2019
Completion Date
October 1, 2032
Last Updated
July 12, 2022
NCT04570423
NCT07249528
NCT06735690
NCT00131014
NCT03050268
NCT06074666
Lead Sponsor
Bellicum Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions